You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

CLINICAL TRIALS PROFILE FOR REPATHA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for REPATHA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01375764 ↗ Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Completed Amgen Phase 2 2011-07-28 The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.
NCT01375777 ↗ Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Completed Amgen Phase 2 2011-07-06 The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
NCT01516879 ↗ Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study Completed Amgen Phase 3 2012-01-05 To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
NCT01588496 ↗ Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities Completed Amgen Phase 2/Phase 3 2012-04-05 A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
NCT01763827 ↗ Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Completed Amgen Phase 3 2013-01-21 The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
NCT01763866 ↗ LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed Amgen Phase 3 2013-01-15 The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for REPATHA

Condition Name

Condition Name for REPATHA
Intervention Trials
Hyperlipidemia 7
Coronary Artery Disease 5
Hypercholesterolemia 3
Familial Hypercholesterolemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for REPATHA
Intervention Trials
Hyperlipidemias 15
Hypercholesterolemia 12
Dyslipidemias 10
Atherosclerosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for REPATHA

Trials by Country

Trials by Country for REPATHA
Location Trials
United States 357
Japan 92
Canada 78
Australia 53
Spain 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for REPATHA
Location Trials
New York 20
California 17
Ohio 17
Florida 14
Texas 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for REPATHA

Clinical Trial Phase

Clinical Trial Phase for REPATHA
Clinical Trial Phase Trials
Phase 4 23
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for REPATHA
Clinical Trial Phase Trials
Completed 23
Recruiting 21
Not yet recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for REPATHA

Sponsor Name

Sponsor Name for REPATHA
Sponsor Trials
Amgen 34
NYU Langone Health 3
Imperial College London 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for REPATHA
Sponsor Trials
Other 54
Industry 40
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.